Because there are few treatments that sufficiently improve uterine infection other than antibiotics, which show increased resistance and risk of infection recurrence, modulation of the AhR pathway using a combination of pharmacological AhR ligands, diet, prebiotics, and AhR ligand-producing bacteria may be a new preventative or therapeutic strategy for endometritis and other infectious or metabolic diseases. Here, AHR is linked to endometritis.